Efficacy of acarbose combined with metformin in the treatment of newly diagnosed type 2 diabetes mellitus with hyperlipidemia / 中国基层医药

ABSTRACT

Objective To observe the efficacy of acarbose combined with metformin in the treatment of newly diagnosed type 2 diabetes mellitus with hyperlipidemia. Methods 160 patients with newly diagnosed type 2 diabetes mellitus with hyperlipidemia were randomly divided into the observation group and the control group,80 cases in each group. The patients in the control group were treated with metformin alone. The patients in the observation group were treated with acarbose plus metformin. The changes of blood glucose and blood lipid index and the adverse reactions were observed before and after treatment. Results After treatment, the blood glucose and blood lipid index were significantly improved in both two groups compared with before treatment. Compared with the control group,the fasting blood glucose (FBG),postprandial 2h blood glucose (2hPG),glycosylated hemoglobin (HbAlc) levels in the observation group were significantly lower (t=5. 18,4. 16,8. 55,all P <0. 01). The total cholesterol (TC), triglyceride (TG),low density lipoprotein cholesterol (LDL-C) levels in the observation group were significantly lower than those in the control group (t=12. 97,7. 72,18. 77,all P<0. 01),the high density lipoprotein cholesterol (HDL-C) level was significantly higher than that in the control group (t=9. 64,P<0. 01). The total effective rate of blood glucose control in the observation group was 93. 7%,which was higher than 81. 3% in the control group,the difference was statistically significant (χ2 =5. 89,P<0. 05). Conclusion Acarbose combined with metformin in the treatment of newly diagnosed type 2 diabetes mellitus with hyperlipidemia has significant clinical efficacy, it is beneficial to control blood glucose and blood lipid level,and worthy of clinical application.